AstraZeneca Plc's COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness in a study participant, four sources told Reuters. AstraZeneca's large, late-stage U.S. trial has been on hold since Sept. 6, after a participant in the company's UK trial fell ill with what was suspected to be a rare spinal inflammatory disorder called transverse myelitis. The sources, who were briefed on the matter but asked to remain anonymous, said they have been told the trial could resume later this week. It was unclear how the FDA would characterize the illness, they said. An FDA spokeswoman...
Full ArticleUS trial of AstraZeneca Covid vaccine may resume this week - Report
WorldNews
0 shares
3 views
You might like
Related news coverage
Drugmakers Resume COVID-19 Vaccine Trials
Newsy
Watch VideoThe race for a COVID-19 vaccine continues for Johnson & Johnson this week.
The company announced it's..
Advertisement
More coverage
Johnson & Johnson Covid-19 Vaccine On Hold
Newsy
Watch VideoThe race for an approved COVID-19 vaccine is dealing with a setback. Johnson & Johnson has paused their late stage..
-
AstraZeneca US COVID-19 vaccine trial may resume as soon as this week
Sydney Morning Herald
-
Astrazeneca Covid-19 vaccine trial in US expected to resume as early as this week
Indian Express
-
Pfizer hopes to produce 100mln COVID-19 vaccine doses before 2021
Proactive Investors
-
Mumbai: 56-year-old man from Thane among 100 volunteers to sign for COVID-19 vaccine trial
Mid-Day